In this article
- FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Following Chemoradiation Therapy
- LAURA Trial – Efficacy and Safety of Osimertinib in Stage III EGFR-Mutated NSCLC
- Recommended Dosage of Osimertinib for Locally Advanced Unresectable Stage III NSCLC
- How CancerFax Helps
On September 25, 2024, the Food and Drug Administration sanctioned osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose condition has remained stable during or after concurrent or sequential platinum-based chemoradiation therapy and whose tumors exhibit EGFR exon 19 deletions or exon 21 L858R mutations, as identified by an FDA-approved assay.
The efficacy was assessed in LAURA (NCT03521154), a double-blind, randomized, placebo-controlled trial involving 216 adult patients with locally advanced, unresectable stage III NSCLC characterized by EGFR exon 19 deletions or exon 21 L858R mutations who had not experienced progression during or after definitive platinum-based chemoradiation within 42 days preceding study randomization. Patients were randomized in a 2:1 ratio to receive either osimertinib 80 mg orally once daily or a placebo until disease progression or intolerable toxicity occurred.
The primary effectiveness endpoint was progression-free survival (PFS) evaluated by blinded independent central review. Supplementary efficacy outcome measures encompassed overall survival (OS). Osimertinib exhibited a statistically significant enhancement in progression-free survival (PFS) relative to placebo, with a hazard ratio of 0.16 (95% CI: 0.10, 0.24; p-value <0.001). The median progression-free survival (PFS) was 39.1 months (95% confidence interval [CI]: 31.5, not estimable [NE]) in the osimertinib group and 5.6 months (95% CI: 3.7, 7.4) in the placebo group.
Although overall survival data were preliminary in this investigation, with only 36% of the pre-specified fatalities reported for the final analysis, no indication of harm was detected.
The prevalent side events, including laboratory abnormalities (≥20%), were lymphopenia, leukopenia, interstitial lung disease/pneumonitis, thrombocytopenia, neutropenia, rash, diarrhea, nail toxicity, musculoskeletal discomfort, cough, and COVID-19 infection.
The advised dosage of osimertinib is 80 mg administered once daily, with or without food, until disease progression or intolerable toxicity occurs.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.